Cargando…

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%. Next-generation sequencing (NGS) is of priority for detecting NTRK fus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Fangfang, Wei, Yuxuan, Zhang, Huan, Jiang, Jizong, Zhang, Peng, Chu, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968138/ https://www.ncbi.nlm.nih.gov/pubmed/35372074 http://dx.doi.org/10.3389/fonc.2022.864666

Ejemplares similares

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
por: Jiang, Tingting, et al.
Publicado: (2021)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021)

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
por: Cervi, Catherine, et al.
Publicado: (2023)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
por: Cappellesso, Rocco, et al.
Publicado: (2022)

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma
por: Yu, Qing-Xiang, et al.
Publicado: (2023)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer
por: Klink, Andrew J., et al.
Publicado: (2022)

NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer()()
por: Choi, Yuri, et al.
Publicado: (2018)

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
por: O’Reilly, E M, et al.
Publicado: (2019)

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
por: Hsiao, Susan J., et al.
Publicado: (2019)

TRK inhibitors in TRK fusion-positive cancers
por: Drilon, A
Publicado: (2019)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis
por: Medford, Arielle J., et al.
Publicado: (2023)

Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
por: Jiang, Tingting, et al.
Publicado: (2022)

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
por: Lazzari, Chiara, et al.
Publicado: (2022)

Case Report: An NTRK1 fusion-positive embryonal rhabdomyosarcoma: clinical presentations, pathological characteristics and genotypic analyses
por: Li, Na-Mei, et al.
Publicado: (2023)

The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform
por: Mohamed, Fawaz, et al.
Publicado: (2022)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
por: Dai, Yinghuan, et al.
Publicado: (2022)

Case Report: A novel LHFPL3::NTRK2 fusion in dysembryoplastic neuroepithelial tumor
por: Chen, Yanming, et al.
Publicado: (2022)

NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma
por: Ghandili, Susanne, et al.
Publicado: (2023)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2022)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma
por: Wang, Hejing, et al.
Publicado: (2023)

The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
por: Qin, Haixia, et al.
Publicado: (2022)

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas
por: Fu, Yao, et al.
Publicado: (2021)

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
por: Moriyama, Etsuko, et al.
Publicado: (2023)

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors
por: Durzyńska, Monika, et al.
Publicado: (2023)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
por: Xu, Chunwei, et al.
Publicado: (2022)

Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs
por: Cho, Hanna, et al.
Publicado: (2021)

Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer
por: Gomez, Daniel Richard, et al.
Publicado: (2018)

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
por: Chen, Yu, et al.
Publicado: (2018)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
por: Zhao, Ruiying, et al.
Publicado: (2021)

EPEN-25. EXCEPTIONAL CLINICAL AND IMAGING RESPONSE TO TRK-INHIBITION IN A PATIENT WITH SUPRATENTORIAL EPENDYMOMA HARBORING NTRK2 GENE FUSION
por: Mangum, Ross, et al.
Publicado: (2020)

Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer
por: Poh, Ashleigh, et al.
Publicado: (2023)

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
por: Frehner, Lorenz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tfmu5p2nnslg900jlr0gia53cu